Skip to main content

Table 3 Certainty in the assessment of efficacy outcomes for anti-calcitonin gene-related peptide monoclonal antibodies for prevention in episodic migraine

From: European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention

 

Certainty assessment

Certainty

Number of studies

Study design

Risk of bias

Inconsistency

Indirectness

Imprecision

Other considerations

Eptinezumab

 1000 mg quarterly ev

1

RCT

not serious

seriousa

not serious

seriousb

none

LOW

Erenumab

 70 monthly sc (except functional improvement)

3

RCT

not serious

not serious

not serious

not serious

none

HIGH

 70 monthly sc (functional improvement)

1

RCT

not serious

seriousa

not serious

not serious

none

MEDIUM

 140 monthly sc

1

RCT

not serious

seriousa

not serious

not serious

none

MEDIUM

Fremanezumab

 225 monthly sc

2

RCT

not serious

not serious

not serious

not serious

none

HIGH

 675 quarterly sc

1

RCT

not serious

seriousa

not serious

not serious

none

MEDIUM

Galcanezumab

 240 mg ld + 120 mg monthly sc

1

RCT

not serious

seriousa

not serious

not serious

none

MEDIUM

 240 mg monthly sc

1

RCT

not serious

seriousa

not serious

not serious

none

MEDIUM

  1. sc Subcutaneous, ev Endovenous, RCT Randomized controlled trial. aInconsistency because of lack of replication; bImprecision because of exploratory study